|
|
Phase II Study of BMS-354825 in Patients With Imatinib Mesylate-Resistant or -Intolerant Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Published Results Related Publications Trial Contact Information Registry Information
Alternate Title
BMS-354825 in Treating Patients With Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia That Did Not Respond to Previous Imatinib Mesylate
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
UCLA-0411071-01 BMS-CA180015, EUDRACT-2004-002517-36, NCT00110097
|
|
|
Objectives Primary - Determine the complete and overall hematologic response rate in patients with blastic phase chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (ALL) with primary or acquired resistance to imatinib mesylate treated with BMS-354825.
Secondary - Determine the durability of hematologic response and time to complete and overall hematologic response in patients treated with this drug.
- Determine the cytogenetic and molecular response in patients treated with this drug.
- Determine the response rate in patients with no evidence of leukemia and in patients whose disease returns to chronic phase after treatment with this drug.
- Determine the hematologic, cytogenetic, and molecular response in patients with imatinib mesylate-intolerant CML or ALL treated with this drug.
- Determine the role of BCR-ABL mRNA expression and point mutations in the BCR-ABL gene as predictors or surrogates of response in patients treated with this drug.
- Determine the health-related quality of life of patients treated with this drug.
- Determine the safety and tolerability of this drug in these patients.
Entry Criteria Disease Characteristics:
Prior/Concurrent Therapy:
Biologic therapy - More than 14 days since prior interferon
Chemotherapy - See Disease Characteristics
- More than 14 days since prior cytarabine
- Prior or concurrent hydroxyurea allowed for treatment of elevated WBC (i.e., WBC > 50,000/mm3)
Endocrine therapy Radiotherapy Surgery Other - No prior BMS-354825
- More than 7 days since prior imatinib mesylate
- At least 7 days since prior low-dose aspirin (≤ 325 mg/day)
- At least 14 days since prior high-dose aspirin (> 325 mg/day)
- More than 14 days since prior targeted small-molecule anticancer agents
- More than 28 days since prior investigational agents
- At least 5 days or 5 half-lives (whichever is longer) since prior and no concurrent drugs that may confer a risk of torsades de pointes, including any of the following:
- Quinidine
- Procainamide
- Disopyramide
- Amiodarone
- Sotalol
- Ibutilide
- Dofetilide
- Erythromycin
- Clarithromycin
- Chlorpromazine
- Haloperidol
- Mesoridazine
- Thioridazine
- Pimozide
- Cisapride
- Bepridil
- Droperidol
- Methadone
- Arsenic
- Chloroquine
- Domperidone
- Halofantrine
- Levomethadyl
- Pentamidine
- Sparfloxacin
- Lidoflazine
- At least 5 days or 5 half-lives (whichever is longer) since prior and no concurrent medications that directly inhibit platelet function (except anagrelide for treatment of thrombocytosis due to CML), including any of the following:
- Dipyridamole
- Epoprostenol
- Eptifibatide
- Clopidogrel
- Cilostazol
- Abciximab
- Ticlopidine
- At least 5 days or 5 half-lives (whichever is longer) since prior and no concurrent anticoagulants (e.g., warfarin or heparin/low molecular weight heparin [e.g., danaparoid, dalteparin, tinzaparin, or enoxaparin])
- Concurrent prophylactic low-dose warfarin allowed for prevention of catheter thrombosis or for heparin-flush of IV lines
- No other concurrent therapy for CML
Patient Characteristics:
Age Performance status Life expectancy Hematopoietic - See Disease Characteristics
- No history of significant bleeding disorder unrelated to CML, including any of the following:
- Diagnosis of congenital bleeding disorder (e.g., von Willebrand's disease)
- Diagnosis of acquired bleeding disorder within the past year (e.g., acquired anti-factor VIII antibodies)
Hepatic - Bilirubin ≤ 2.0 times upper limit of normal (ULN)
- ALT and AST ≤ 2.5 times ULN
Renal - Creatinine ≤ 1.5 times ULN
- Total or ionized calcium normal*
[Note: *Supplementation allowed] Cardiovascular - No myocardial infarction within the past 6 months
- No uncontrolled angina within the past 3 months
- No congestive heart failure within the past 3 months
- No diagnosis or suspicion of congenital long QT syndrome
- No history of clinically significant ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
- No prolonged QTc interval (i.e., > 450 msec) on EKG by Bazett's correction or Fridericia correction
- No history of second or third degree heart block
- Patients with pacemakers may be eligible
- No heart rate consistently < 50 beats/minute on EKG
- No uncontrolled hypertension
- No other uncontrolled or significant cardiovascular disease
Gastrointestinal - No clinically significant gastrointestinal tract bleeding within the past 6 months
- No evidence of digestive dysfunction that would preclude study participation
Other - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception 1 month before, during, and for at least 3 months after completion of study treatment
- Potassium normal*
- Magnesium normal*
- No other serious uncontrolled medical disorder or active infection that would preclude study participation
- No dementia or altered mental status that would preclude giving informed consent
- No evidence of organ dysfunction that would preclude study participation
- No prisoners or patients who are compulsorily detained (involuntarily incarcerated) for treatment of a psychiatric or physical (e.g., infectious disease) illness
- No other incurable malignancy
[Note: *Supplementation allowed] Expected Enrollment A minimum of 60 patients (at least 30 with blastic phase chronic myelogenous leukemia and at least 30 with acute lymphoblastic leukemia) will be accrued for this study within 6 months. Outline This is an open-label, multicenter study. Patients receive oral BMS-354825 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, every 2 weeks for the first 3 courses, monthly thereafter during study treatment, and 30 days after completion of study treatment. After completion of study treatment, patients are followed for at least 30 days. Published ResultsCoutre S, Martinelli G, Dombret H, et al.: Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): the CA180015 'START-L' study. [Abstract] J Clin Oncol 24 (Suppl 18): A-6528, 344s, 2006. Ottmann OG, Martinelli G, Dombret H, et al.: A phase II study of dasatinib in patients with chronic myeloid leukemia (CML) in lymphoid blast crisis or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib: the ‘START-L’ CA180015 study. [Abstract] Blood 106 (11): A-42, 2005. Related PublicationsCortes J, Rousselot P, Kim DW, et al.: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109 (8): 3207-13, 2007.[PUBMED Abstract]
Trial Contact Information
Trial Lead Organizations Jonsson Comprehensive Cancer Center at UCLA | | | Neil Shah, MD, Protocol chair | | | |
Registry Information | | Official Title | | A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate | | Trial Start Date | | 2005-01-11 | | Registered in ClinicalTrials.gov | | NCT00110097 | | Date Submitted to PDQ | | 2005-02-17 | | Information Last Verified | | 2006-04-11 | | NCI Grant/Contract Number | | CA16042 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|